From: Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) for the treatment of malignant mesothelioma
Data items | Number | Percent |
---|---|---|
Patients with primary non-access for PIPAC | 7 / 29 | 24.1 |
Patients with secondary non-access for PIPAC | 3 / 29 | 10.3 |
PIPAC procedures per patient (n) | ||
- 10 x | 1 / 29 | 3.4 |
- 7 x | 1 / 29 | 3.4 |
- 5 x | 1 / 29 | 3.4 |
- 4 x | 4 / 29 | 13.8 |
- 3 x | 5 / 29 | 17.2 |
- 2 x | 8 / 29 | 27.6 |
- 1 x | 5 / 29 | 17.2 |
- 0 x | 4 / 29 | 13.8 |
Number of successful PIPAC/PITAC procedures | 79 | 100 |
- Laparoscopic PIPAC procedures | 71 / 79 | 89.9 |
- Laparotomy, adhesiolysis +/− debulking & PIPAC | 3 / 79 | 3.8 |
- PITAC procedures | 5 / 79 | 6.3 |
Overall postoperative morbidity/mortality (CTCAE v 4.0) | ||
- Grade 1 | 23 / 79 | 29.1 |
- Grade 2 | 7 / 79 | 8.9 |
- Grade 3 | 1 / 79 | 1.3 |
- Grade 4 | 2 / 79 | 2.5 |
- Grade 5 | 1 / 79 | 1.3 |
Media survival time (days) according to tumor regression grade | ||
- Grade 0 | 6 | 226 (31–708) |
- Grade 1 | 11 | 360 (135–529) |
- Grade 2+ | 8 | 360 (175–1331) |